{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:11:19Z","timestamp":1762254679827,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00280-023-04607-7","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T20:22:33Z","timestamp":1698524553000},"page":"121-127","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer"],"prefix":"10.1007","volume":"93","author":[{"given":"Yao","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-6541","authenticated-orcid":false,"given":"Osamu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuki","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"issue":"4","key":"4607_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2188\/jea.JE20120162","volume":"23","author":"Y Lin","year":"2013","unstructured":"Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y, Ueda J, Wei W, Inoue M, Tanaka H (2013) Epidemiology of esophageal cancer in Japan and China. J Epidemiol 23(4):233\u2013242","journal-title":"J Epidemiol"},{"issue":"9319","key":"4607_CR2","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/S0140-6736(02)08651-8","volume":"359","author":"Medical Research Council Oesophageal Cancer Working Party","year":"2002","unstructured":"Medical Research Council Oesophageal Cancer Working Party (2002) Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet (London, England) 359(9319):1727\u20131733","journal-title":"Lancet (London, England)"},{"key":"4607_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005533","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Kitagawa Y, Takemura R, Okui J, Okamura A, Kawakubo H, Muto M, Kakeji Y, Takeuchi H, Watanabe M, Doki Y (2022) Real-world evaluation of the efficacy of neoadjuvant DCF over CF in esophageal squamous cell carcinoma: propensity score matched analysis from 85 authorized institutes for esophageal cancer in Japan. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000005533","journal-title":"Ann Surg"},{"issue":"11","key":"4607_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455\u20131460. https:\/\/doi.org\/10.1111\/cas.12274","journal-title":"Cancer Sci"},{"issue":"5","key":"4607_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40262-018-0719-5","volume":"58","author":"S Bins","year":"2019","unstructured":"Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW (2019) Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients. Clin Pharmacokinet 58(5):651\u2013658. https:\/\/doi.org\/10.1007\/s40262-018-0719-5","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"4607_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00228-020-02879-z","volume":"76","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Ning C, Wang Z, Wang Y, Zheng M, Zhang S, Lu Y, Zhang Y, Li N, Chen X, Zhao D (2020) Influences of ABC transporter and CYP3A4\/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects. Eur J Clin Pharmacol 76(8):1125\u20131133. https:\/\/doi.org\/10.1007\/s00228-020-02879-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4607_CR7","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"WE Evans","year":"2003","unstructured":"Evans WE, McLeod HL (2003) Pharmacogenomics\u2013drug disposition, drug targets, and side effects. N Engl J Med 348(6):538\u2013549","journal-title":"N Engl J Med"},{"issue":"1","key":"4607_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12885-019-5438-2","volume":"19","author":"K Sone","year":"2019","unstructured":"Sone K, Oguri T, Uemura T, Takeuchi A, Fukuda S, Takakuwa O, Maeno K, Fukumitsu K, Kanemitsu Y, Ohkubo H, Takemura M, Ito Y, Niimi A (2019) Genetic variation in the ATP binding cassette transporter ABCC10 is associated with neutropenia for docetaxel in Japanese lung cancer patients cohort. BMC Cancer 19(1):246. https:\/\/doi.org\/10.1186\/s12885-019-5438-2","journal-title":"BMC Cancer"},{"key":"4607_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.08.001","author":"SW Lam","year":"2016","unstructured":"Lam SW, Guchelaar HJ, Boven E (2016) The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev. https:\/\/doi.org\/10.1016\/j.ctrv.2016.08.001","journal-title":"Cancer Treat Rev"},{"issue":"6731","key":"4607_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/19986","volume":"399","author":"H Tsukaguchi","year":"1999","unstructured":"Tsukaguchi H, Tokui T, Mackenzie B, Berger UV, Chen XZ, Wang Y, Brubaker RF, Hediger MA (1999) A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature 399(6731):70\u201375","journal-title":"Nature"},{"issue":"2","key":"4607_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3892\/ol.2012.1014","volume":"5","author":"T Minegaki","year":"2013","unstructured":"Minegaki T, Takara K, Hamaguchi R, Tsujimoto M, Nishiguchi K (2013) Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin. Oncol Lett 5(2):427\u2013434","journal-title":"Oncol Lett"},{"issue":"4","key":"4607_CR12","doi-asserted-by":"publisher","first-page":"321","DOI":"10.7150\/ijms.7654","volume":"11","author":"T Minegaki","year":"2014","unstructured":"Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K (2014) Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil\/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 11(4):321\u2013326. https:\/\/doi.org\/10.7150\/ijms.7654","journal-title":"Int J Med Sci"},{"issue":"2","key":"4607_CR13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.ygeno.2019.07.006","volume":"112","author":"A Yousefian-Jazi","year":"2020","unstructured":"Yousefian-Jazi A, Jung J, Choi JK, Choi J (2020) Functional annotation of noncoding causal variants in autoimmune diseases. Genomics 112(2):1208\u20131213. https:\/\/doi.org\/10.1016\/j.ygeno.2019.07.006","journal-title":"Genomics"},{"issue":"12","key":"4607_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1046\/j.1464-5491.2002.00844.x","volume":"19","author":"A Kitamura","year":"2002","unstructured":"Kitamura A, Hasegawa G, Obayashi H, Kamiuchi K, Ishii M, Yano M, Tanaka T, Yamaguchi M, Shigeta H, Ogata M, Nakamura N, Yoshikawa T (2002) Interleukin-6 polymorphism (-634C\/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med J Br Diabet Assoc 19(12):1000\u20131005","journal-title":"Diabet Med J Br Diabet Assoc"},{"issue":"2","key":"4607_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1006\/bbrc.1999.0796","volume":"259","author":"BH Rovin","year":"1999","unstructured":"Rovin BH, Lu L, Saxena R (1999) A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259(2):344\u2013348","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"4607_CR16","first-page":"381","volume":"16","author":"K Sakamoto","year":"2006","unstructured":"Sakamoto K, Oka M, Yoshino S, Hazama S, Abe T, Okayama N, Hinoda Y (2006) Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncol Rep 16(2):381\u2013387","journal-title":"Oncol Rep"},{"issue":"3","key":"4607_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10388-016-0522-z","volume":"13","author":"K Fujita","year":"2016","unstructured":"Fujita K, Motoyama S, Sato Y, Yoshino K, Sasaki T, Liu J, Niioka T, Anbai A, Minamiya Y, Miura M (2016) IL-6 and MCP-1 genetic polymorphisms are predictive of decreased platelet counts caused by chemoradiotherapy in esophageal cancer. Esophagus 13(3):264\u2013269. https:\/\/doi.org\/10.1007\/s10388-016-0522-z","journal-title":"Esophagus"},{"key":"4607_CR18","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. Wiley"},{"issue":"1","key":"4607_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341","journal-title":"Nephron"},{"issue":"2","key":"4607_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00280-020-04118-9","volume":"86","author":"H Nomura","year":"2020","unstructured":"Nomura H, Tsuji D, Demachi K, Mochizuki N, Matsuzawa H, Yano T, Daiko H, Fujii S, Kojima T, Itoh K, Kawasaki T (2020) ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Cancer Chemother Pharmacol 86(2):315\u2013324. https:\/\/doi.org\/10.1007\/s00280-020-04118-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4607_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s10388-021-00865-7","volume":"19","author":"K Fujita","year":"2022","unstructured":"Fujita K, Motoyama S, Sato Y, Wakita A, Nagaki Y, Minamiya Y, Miura M (2022) Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy. Esophagus Off J Japan Esophageal Soc 19(1):146\u2013152. https:\/\/doi.org\/10.1007\/s10388-021-00865-7","journal-title":"Esophagus Off J Japan Esophageal Soc"},{"issue":"4","key":"4607_CR22","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.3892\/ol.2018.9236","volume":"16","author":"Y Arakawa","year":"2018","unstructured":"Arakawa Y, Shirai Y, Hayashi K, Tanaka Y, Matsumoto A, Nishikawa K, Yano S (2018) Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma. Oncol Lett 16(4):5455\u20135462. https:\/\/doi.org\/10.3892\/ol.2018.9236","journal-title":"Oncol Lett"},{"issue":"1","key":"4607_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2307\/2336755","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D (1993) Bias reduction of maximum likelihood estimates. Biometrika 80(1):27\u201338. https:\/\/doi.org\/10.2307\/2336755","journal-title":"Biometrika"},{"issue":"1","key":"4607_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/tpj.2010.20","volume":"11","author":"S Laechelt","year":"2011","unstructured":"Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S (2011) Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J 11(1):25\u201334. https:\/\/doi.org\/10.1038\/tpj.2010.20","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"4607_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00008571-200405000-00007","volume":"14","author":"MV Mandola","year":"2004","unstructured":"Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz H-J, Ladner RD (2004) A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics Genom 14(5):319\u2013327","journal-title":"Pharmacogenetics Genom"},{"issue":"17","key":"4607_CR26","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1158\/1078-0432.CCR-04-0169","volume":"10","author":"T Lecomte","year":"2004","unstructured":"Lecomte T, Ferraz J-M, Zinzindohou\u00e9 F, Loriot M-A, Tregouet D-A, Landi B, Berger A, Cugnenc P-H, Jian R, Beaune P, Laurent-Puig P (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10(17):5880\u20135888. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0169","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4607_CR27","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1111\/jth.15891","volume":"20","author":"T Chu","year":"2022","unstructured":"Chu T, Hu S, Qi J, Li X, Zhang X, Tang Y, Yang M, Xu Y, Ruan C-G, Han Y, Wu D-P (2022) Bifunctional effect of the inflammatory cytokine tumor necrosis factor \u03b1 on megakaryopoiesis and platelet production. J Thromb Haemost: JTH 20(12):2998\u20133010. https:\/\/doi.org\/10.1111\/jth.15891","journal-title":"J Thromb Haemost: JTH"},{"issue":"6","key":"4607_CR28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3892\/br.2017.908","volume":"6","author":"M Nourian","year":"2017","unstructured":"Nourian M, Chaleshi V, Pishkar L, Azimzadeh P, Baradaran Ghavami S, Balaii H, Alinaghi S, Shahrokh S, Asadzadeh Aghdaei H, Zali MR (2017) Evaluation of tumor necrosis factor (TNF)-\u03b1 mRNA expression level and the rs1799964 polymorphism of the TNF-\u03b1 gene in peripheral mononuclear cells of patients with inflammatory bowel diseases. Biomed Rep 6(6):698\u2013702. https:\/\/doi.org\/10.3892\/br.2017.908","journal-title":"Biomed Rep"},{"issue":"11","key":"4607_CR29","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1056\/NEJM199809103391107","volume":"339","author":"K Kaushansky","year":"1998","unstructured":"Kaushansky K (1998) Thrombopoietin. N Engl J Med 339(11):746\u2013754","journal-title":"N Engl J Med"},{"issue":"9","key":"4607_CR30","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","volume":"98","author":"A Kaser","year":"2001","unstructured":"Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H (2001) Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98(9):2720\u20132725","journal-title":"Blood"},{"issue":"1","key":"4607_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bbi.2012.10.012","volume":"27","author":"SE Mahoney","year":"2013","unstructured":"Mahoney SE, Davis JM, Murphy EA, McClellan JL, Gordon B, Pena MM (2013) Effects of 5-fluorouracil chemotherapy on fatigue: role of MCP-1. Brain Behav Immun 27(1):155\u2013161. https:\/\/doi.org\/10.1016\/j.bbi.2012.10.012","journal-title":"Brain Behav Immun"},{"issue":"1","key":"4607_CR32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3892\/mco.2016.1081","volume":"6","author":"K Sakamoto","year":"2017","unstructured":"Sakamoto K, Takeda S, Kanekiyo S, Nishiyama M, Kitahara M, Ueno T, Yamamoto S, Yoshino S, Hazama S, Okayama N, Nagano H (2017) Association of tumor necrosis factor-\u03b1 polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer. Mol Clin Oncol 6(1):125\u2013129. https:\/\/doi.org\/10.3892\/mco.2016.1081","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"4607_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cpt.2667","volume":"112","author":"C White","year":"2022","unstructured":"White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, Michael M, Ackland S (2022) Dihydropyrimidine dehydrogenase deficiency and implementation of upfront DPYD genotyping. Clin Pharmacol Ther 112(4):791\u2013802. https:\/\/doi.org\/10.1002\/cpt.2667","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4607_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.clpt.2004.01.001","volume":"75","author":"FK Engels","year":"2004","unstructured":"Engels FK, Ten Tije AJ, Baker SD, Lee CKK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75(5):448\u2013454","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04607-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:03:30Z","timestamp":1707368610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04607-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4607"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04607-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuhiro Kodera reports personal fees from Ono Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd. and research funds from Chugai Pharmaceutical Co., Ltd., Tiho Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd. Yuichi Ando reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Bayer Holding Ltd., research funds from Beigene, and grants from Geo Holdings outside the submitted work. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects (Ministry of Health, Labor and Welfare, Japan) and the Declaration of Helsinki. This study was approved by the Institutional Review Board (approval no. 2021-0091). All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}